Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 equivalence study of ustekinumab injection versus Stelara in moderate to severe plaque psoriasis
ChiCTR2300069534Phase 3Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of ustekinumab in plaque psoriasis (2 arms), sponsored by First Hospital of China Medical University. Primary endpoint: Percent change from baseline in PASI score at Week 12. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
ustekinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ChiCTR2300069534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069534.